Ratings New Horizon Health Limited

Equities

Market Closed - Hong Kong S.E. Other stock markets 08:08:30 27/03/2024 GMT			5-day change	1st Jan Change
14.14 ^HKD	-19.75%		-.--%	-38.92%

04-08	New Horizon Health Limited Announces Board Appointments	CI
03-28	New Horizon Health Limited Announces Delay in Publication Annual Results for the Year Ended December 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The company's profit outlook over the next few years is a strong asset.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

With an expected P/E ratio at 99.04 and 18.42 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
NEW HORIZON HEALTH LIMITED	-38.92%	812M		-
BIOMÉRIEUX	-1.29%	12.5B		B+
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-9.59%	7.67B		B-
LANTHEUS HOLDINGS, INC.	+26.10%	5.36B		C
DIASORIN S.P.A.	-0.45%	5.26B		B
AUTOBIO DIAGNOSTICS CO., LTD.	+0.02%	4.57B		C
10X GENOMICS, INC.	-53.02%	3.15B		D+
ANDON HEALTH CO., LTD.	+6.42%	2.59B	-	-
VITROLIFE AB	-10.89%	2.06B		B-
GUANGZHOU WONDFO BIOTECH CO.,LTD	-8.29%	1.79B		D+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality